Moneycontrol PRO
Sansaar
HomeNewsBusinessCompaniesCadila Healthcare jumps after US FDA clears Moraiya plant

Cadila Healthcare jumps after US FDA clears Moraiya plant

Shares of pharma major Cadila Healthcare surged over 5% on Tuesday morning after the US Food and Drugs Administration (FDA) gave a clearance to the company's facilities at Moraiya in Gujarat.

July 17, 2012 / 12:19 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Moneycontrol Bureau


    Shares of pharma major Cadila Healthcare surged over 5% on Tuesday morning after the US Food and Drugs Administration (FDA) gave a clearance to the company's facilities at Moraiya in Gujarat.


    The US FDA had in 2011 sent a warning letter to Cadila saying it had violated some rules related to manufacturing practice at Moraiya plant. The warning was based on inspections that the US drug regulator carried out at the facility, which is used to make tablets, capsules and injectible drugs.


    "During our January 17 - February 3, 2011 inspection of your pharmaceutical manufacturing facility, at Moraiya, Gujarat, investigators from FDA identified significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals," US FDA had said then.


    It has now sent another letter to the company clearing the said facility following a re-inspection.


    "The company has received a letter from US FDA, conveying that the facilities at Moraiya are acceptable. With this, the warning letter issued by them earlier is resolved," Cadila said in a notice to stock exchanges.


    Hitesh Mahida, an analyst at Fortune Equity Brokers said that apart from oral dosage form launches the Moraiya facility also houses injectible and nasal spray unit, which being limited in competition, should improve profitability of the company’s US business going forward.


    "Company has filed for 18 injectible products and 7 Nasal sprays (most nasal spray generic products have less than 4 players in the market) from this facility. Cadila has filed for Nasal spray drug Azelastine which alone can generate close to USD 20 million of sales for Cadila," he said.

    At 10:30hrs, Cadila shares were up 4% at Rs 831.50 on NSE.

    first published: Jul 17, 2012 10:53 am

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347